Study finds incidence of microbial keratitis associated with overnight orthokeratology

News
Article

The incidence was comparable to that of daily wear soft contact lenses.

Child putting in contact lenses at desk Image credit: AdobeStock/irena_geo

Image credit: AdobeStock/irena_geo

A recent study found that orthokeratology lenses, which are worn overnight to reshape the cornea to improve vision and eliminate the need for correction during the day, was associated with an incidence rate of microbial keratitis similar to both that seen with the use of daily wear contact lenses and results reported in previous studies,1 according to first author Takahiro Hiraoka, MD, PhD, and colleagues. He is from the Department of Ophthalmology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.

The research team conducted a retrospective multicenter study to determine the incidence of microbial keratitis among Japanese patients wearing orthokeratology lenses, referred to as ortho-k lenses.

This study, which included 1,438 patients (753 males, 685 females; mean age, 12.7 ± 5.4 years), was conducted at 4 hospitals in Japan. All patients had been prescribed the orthokeratology lenses and wore them for a minimum of 3 months.

The investigators collected data from the medical records on patient demographics, lens characteristics, lens care systems and presence of microbial keratitis. They calculated the time that the patients wore the lenses from the fitting date to the patient's last visit, with the total years of lens wear used as person-years of lens wear. The incidence of microbial keratitis was calculated by dividing the number of infected cases by the total person-years of lens wear for all enrolled participants, the authors explained.

The data analysis showed that the mean duration of orthokeratology lens wear was 5.2 ± 4.5 years, and the mean lens power was -3.52 ± 1.41 diopters. The total person-years of lens wear for all patients was 7,415.

Among the study patients, 4 cases of microbial keratitis occurred, for an overall microbial keratitis incidence of 5.4 (95% confidence interval, 1.0–9.8) per 10,000 patient-years.

The investigators commented, “This study represents the largest sample size to date for estimating the incidence of microbial keratitis associated with ortho-k lenses. The incidence was similar to or slightly lower than that of previous studies on ortho-k-related microbial keratitis and also comparable to that of daily wear soft contact lenses.”

Reference:
  1. Hiraoka T, Matsumura S, Hori Y, et al. Incidence of microbial keratitis associated with overnight orthokeratology: a multicenter collaborative study. Jpn J Ophthalmol. 2024; https://doi.org/10.1007/s10384-024-01137-4
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.